Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain

Neuroscience
S KroesenH Winkler

Abstract

We have measured the messenger RNA levels of chromogranins A and B and secretogranin II in various brain regions of rats subchronically treated with various antipsychotic drugs. Since, as shown previously, the messenger RNA levels of these peptides are increased when neurons are stimulated, we hoped to identify by this approach those nuclei which are subchronically influenced by these drugs. The drugs chosen were the neuroleptic halperidol, a blocker of dopamine receptors, the atypical antipsychotic clozapine, which in addition to blocking dopamine receptors also blocks those for serotonin, and citalopram, a specific serotonin reuptake inhibitor. In agreement with previous data on neuropeptide messenger RNAs, we found in the dorsolateral striatum an increase of the secretogranin II messenger RNA levels after haloperidol and a much smaller one after clozapine. In the nucleus accumbens and in the bed nucleus of the stria terminalis, both compounds had a comparable positive effect. These differential effects can be attributed to a different action of these drugs on dopamine receptor subtypes. In the zona incerta, clozapine decreased the secretogranin II and chromogranin A message, whereas in the dorsal raphe it led to an increase....Continue Reading

References

Jan 1, 1992·Annals of the New York Academy of Sciences·K M MerchantD M Dorsa
Aug 1, 1992·Neuroscience·H Winkler, R Fischer-Colbrie
Jan 1, 1989·Journal of Molecular Neuroscience : MN·S Forss-PetterJ G Sutcliffe
Jan 25, 1988·FEBS Letters·A IacangeloL E Eiden
Dec 23, 1988·Nucleic Acids Research·H H GerdesW B Huttner
Aug 1, 1985·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J A NolanR Hogue-Angeletti
Dec 1, 1985·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·M MarcinkiewiczM Chrétien
Sep 1, 1967·British Journal of Pharmacology and Chemotherapy·F H SchneiderH Winkler
Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·F TangJ P Schwartz
Jun 15, 1983·Biochemical and Biophysical Research Communications·S L SabolJ S Hong
Sep 1, 1994·Acta Physiologica Scandinavica·K B Helle, R H Angeletti
Jan 1, 1994·Peptides·M K SchäferE Weihe
Nov 8, 1993·FEBS Letters·N ReinischC J Wiedermann
Sep 17, 1993·Brain Research·C J Gibson, D G Munoz
Jan 1, 1991·The European Journal of Neuroscience·S. K. MahataH. Winkler

❮ Previous
Next ❯

Citations

Jan 1, 1997·Journal of Neural Transmission·E SchulzH Remschmidt
Oct 28, 1998·Journal of Psychiatric Research·C FleischhakerH Remschmidt
Dec 11, 1999·Schizophrenia Research·P J Harrison
Nov 20, 2002·Journal of Neurochemistry·Outi KontkanenEero Castrén
Aug 8, 2014·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Stefan KargerMathias Fasshauer
Jun 11, 1998·The Journal of Biological Chemistry·J Ciesielski-TreskaM F Bader

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.